Register for our free email digests:
Division of f-star GMBH
Latest From F-star GMBH
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2017.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
'Asset-centric' bispecific antibody developer F-star has agreed an option deal for a package of immuno-oncology-focused antibodies with Merck of Germany.
PwC partner Dmitri Drone explained that a deal for an asset with high commercial expectations is best structured with more emphasis on pre-approval than post-approval payments. A post-approval focus on shared risk is more appropriate when an asset is licensed at an earlier stage of development.
- Synthesis Technologies, Production Processes
- Large Molecule
- Therapeutic Areas
- f-star Biotechnology Research & Development Co.
- Western Europe
- Parent & Subsidiaries
- f-star GMBH
- F-star GMBH
- Senior Management
John Haurum, PhD, CEO
Tolga Hassan, CFO
Jane Dancer, PhD, CBO
Neil Brewis, PhD, CSO
- Contact Info
Phone: (43) 72055 4215
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.